Xponance, Inc. Apellis Pharmaceuticals, Inc. Transaction History

Xponance, Inc.

$10.2 Billion
Q3 2024

A detailed history of Xponance, Inc. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Xponance, Inc. holds 13,323 shares of APLS stock, worth $441,524. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,323

Previous 13,773 3.27%

Holding current value

$441,524

Previous $528,000 27.27%

% of portfolio

0.0%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$28.84 - $41.15 $12,978 - $18,517	-450 Reduced 3.27%	13,323 $384,000
Q2 2024 Aug 14, 2024	BUY	$38.07 - $59.71 $36,851 - $57,799	968 Added 7.56%	13,773 $528,000
Q1 2024 May 13, 2024	SELL	$55.39 - $72.47 $6,757 - $8,841	-122 Reduced 0.94%	12,805 $752,000
Q4 2023 Jan 31, 2024	SELL	$37.14 - $64.82 $34,874 - $60,865	-939 Reduced 6.77%	12,927 $773,000
Q3 2023 Oct 23, 2023	SELL	$23.65 - $89.22 $4,280 - $16,148	-181 Reduced 1.29%	13,866 $527,000
Q2 2023 Jul 13, 2023	BUY	$76.68 - $93.31 $661,901 - $805,451	8,632 Added 159.41%	14,047 $1.28 Million
Q1 2023 Apr 17, 2023	BUY	$46.59 - $66.96 $2,143 - $3,080	46 Added 0.86%	5,415 $357,000
Q4 2022 Jan 23, 2023	BUY	$43.24 - $61.04 $4,929 - $6,958	114 Added 2.17%	5,369 $0
Q3 2022 Oct 24, 2022	BUY	$44.76 - $69.66 $16,561 - $25,774	370 Added 7.57%	5,255 $359,000
Q2 2022 Aug 02, 2022	BUY	$35.07 - $59.21 $171,316 - $289,240	4,885 New	4,885 $221,000
Q3 2021 Nov 05, 2021	SELL	$31.4 - $69.84 $111,658 - $248,351	-3,556 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$40.9 - $64.9 $145,440 - $230,784	3,556 New	3,556 $225,000

Others Institutions Holding APLS

# of Institutions

308

Shares Held

115M

Call Options Held

3.85M

Put Options Held

1.09M

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xponance, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Xponance, Inc. with notifications on news.

Account